Back to Investor Brief

Investor Brief · Part 2

Customer Selection: who Pause-Health.ai sells to and why now

A focused B2B motion targeting integrated health systems and value-based payers — the two buyer archetypes that own the menopause care problem and have budget to fix it.

Integrated Delivery Networks (IDNs)

~120 systems in the US with 5+ hospitals and OB/GYN service lines

Multi-specialty providers serving 250k–2M attributed lives. Already invested in Epic or Cerner, with active ambulatory transformation programs.

  • Acute painMenopause patients ricochet across primary care, OB/GYN, behavioral health, and cardiology. Care plans are inconsistent and outcomes are not measured.
  • Economic buyerChief Medical Officer / VP Ambulatory Services
  • Internal championService line director for Women's Health
  • Contract shapeAnnual SaaS, $250k–$1.2M ACV, gain-share on quality metrics
  • Why nowCMS quality programs now include menopause-adjacent outcomes; women 40-60 are the highest-margin commercial cohort.

Value-Based Care Payers

Top 25 commercial + Medicare Advantage plans (HEDIS-driven)

Plans with at-risk arrangements where avoidable utilization for midlife women materially impacts MLR.

  • Acute painMidlife women drive disproportionate ER visits for cardiac, mental health, and undifferentiated symptoms — many are unrecognized menopause presentations.
  • Economic buyerVP Clinical Programs / Chief Medical Officer
  • Internal championDirector of Women's Health or Behavioral Health programs
  • Contract shapePMPM ($1.50–$4.00 per attributed midlife woman) + outcomes incentive
  • Why nowSTAR ratings and HEDIS controlling-high-blood-pressure, depression screening, and care coordination measures all benefit.

Academic Medical Centers

~80 AMCs with active menopause or midlife women's research programs

Tertiary providers with clinical research infrastructure, IRBs, and willingness to co-author evidence.

  • Acute painHave the expertise but lack tooling to operationalize specialty guidelines across general OB/GYN and primary care.
  • Economic buyerDepartment Chair (OB/GYN or Internal Medicine)
  • Internal championDirector of a midlife/menopause specialty clinic
  • Contract shapeResearch + clinical SaaS hybrid, $150k–$500k ACV
  • Why nowFunding for women's health research is at a 20-year high; AMCs need partners to translate guidelines into workflow.

Buying committee personas

Service Line Director, Women's Health

IDN / health system

  • Reduce variation in menopause care across affiliated clinics
  • Hit quality and patient-experience targets
  • Demonstrate ROI to operating leadership

Chief Medical Officer

IDN or payer

  • Reduce avoidable utilization for midlife women
  • Show measurable improvements in HEDIS / patient outcomes
  • Find a defensible AI strategy with clinical guardrails

Medical Director, Women's Health programs

Payer

  • Build at-risk products that win employer business
  • Reduce mental-health and cardiometabolic spend in the 40-60 cohort
  • Operationalize menopause clinical guidelines at population scale

Director of Clinical Informatics

IDN / AMC

  • Approve FHIR-native, SMART-on-FHIR-capable apps
  • Ensure audit-ready, explainable AI decisions
  • Avoid yet another EHR side-system

Market sizing

Sequencing

Land with 3–5 forward-leaning IDNs and 1–2 value-based payers in Year 1 to anchor outcomes evidence. Expand into peer systems via clinical advisory referrals and into employer-paid carve-outs through payer relationships. Academic medical centers serve as evidence partners, not initial ARR.